https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):92025-01-23 00:00:002025-01-23 00:00:00WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-23 / Clin Transl Oncol 2024 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-23 / Clin Transl Oncol 2024 Dec;2024-12-23 00:00:002024-12-23 00:00:00Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-16 / Oncol Lett 2025 Jan;29(1):6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-16 / Oncol Lett 2025 Jan;29(1):62024-10-16 00:00:002024-10-16 00:00:00Anticancer effect of the oncolytic Newcastle disease virus harboring the PTEN gene on glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-03 / Neurol Sci 2024 Jun;45(6):2561-2578
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-03 / Neurol Sci 2024 Jun;45(6):2561-25782024-02-03 00:00:002024-02-03 00:00:00A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-01-05 / EBioMedicine 2024 Jan;100:104963
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-01-05 / EBioMedicine 2024 Jan;100:1049632024-01-05 00:00:002024-01-05 00:00:00Glioblastoma vaccines: past, present, and opportunities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-112023-11-14 00:00:002023-11-14 00:00:00Targeting immunogenic cell death for glioma immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-12 / Med Oncol 2023 Nov;40(12):354
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-12 / Med Oncol 2023 Nov;40(12):3542023-11-12 00:00:002023-11-12 00:00:00Therapeutic cell-based vaccines for glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-19 / Methods Cell Biol 2024;183:51-113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-19 / Methods Cell Biol 2024;183:51-1132023-10-19 00:00:002024-04-20 10:47:17Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-31 / Cancers (Basel) 2023 Jul;15(15)2023-07-31 00:00:002023-07-31 00:00:00Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
